Overview

A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations

Status:
Completed

Trial end date:
2020-09-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetic (PK) and safety of an age-appropriate tofacitinib Modified Release (MR) formulation with varying level of enteric coating. The effect of food on the PK of age-appropriate tofacitinib MR formulation with the lowest and higher levels of enteric coating will also be assessed.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Tofacitinib